On Tuesday, the U.S. Food and Drug Administration’s advisory committee voted to back Pfizer's vaccine for kids ages 5 to 11.
The vaccine could be available for some 28 million children by next week.
Dr. Bian Labus, an infectious disease specialist with UNLV tells 13 Action News the decision is a game changer, especially because these kids are in school.
